Agreement On SPC Manufacturing Waiver Reached, Benefitting EU Generic, Biosimilar Industry 14/02/2019 by David Branigan, Intellectual Property Watch 2 Comments The European Council reached a political agreement today on the SPC Manufacturing Waiver, which will allow the manufacture of generic and biosimilar medicines in the European Union for export and stockpiling during the period of extended patent protection provided for by the EU. This waiver will enable EU generic and biosimilar industries to benefit from sales outside the EU where patents have already expired, and to prepare to provide the EU market as soon as the extended period of patent protection ends.
‘No More Paying For The Rich World’s Medicine’ – White House 13/02/2019 by Intellectual Property Watch 2 Comments The Trump administration yesterday made some firm statements about reducing health care and drug prices for American consumers and making costs more transparent. The statements again appear to focus on other countries paying more for US-made drugs but also promote generic drugs.
Malaysia Still Under Pressure To Make Hepatitis C Medicine More Expensive 13/02/2019 by William New, Intellectual Property Watch Leave a Comment The government of Malaysia continues to face pressure from the United States pharmaceutical industry and potentially the US government to undo an action taken to make a key hepatitis C medicine more affordable in the country. Now Médecins Sans Frontières (MSF, Doctors Without Borders) has weighed in to defend the government’s right to use a patent flexibility in global trade law that allows them to take such actions on behalf of their citizens.
WIPO Event: AI On All Fronts – Health, Cities, Agriculture – But Investment Needed; Europe Lagging 12/02/2019 by Catherine Saez, Intellectual Property Watch 1 Comment Artificial intelligence is with us to stay, and you can expect solutions to great challenges, but governments should be prepared to invest in education and research to keep up with the two global leaders of the field: the United States and China. This is in essence what several speakers said recently at an event held at the World Intellectual Property Organization.
Women On The Rise In Patent Filings, But Still Underutilised Potential, USPTO Says 12/02/2019 by David Branigan, Intellectual Property Watch Leave a Comment The United States Patent and Trademark Office (USPTO) released a report on 11 February showing an increase in US patents that include at least one woman inventor from 7 percent in the 1980s to 21 percent by 2016. This is still a “small minority” of patented inventors, the report finds, and suggests that it indicates an “underutilisation” of women’s innovative potential.
TRIPS Council To Look At IP And The Public Interest, Business Interest 11/02/2019 by William New, Intellectual Property Watch Leave a Comment The World Trade Organization is the prime gathering point for the world’s governments to discuss and negotiate on policies of the day. A decades-long swinging pendulum within the WTO’s committee on trade and intellectual property is IP’s contribution to innovation and economy and its contribution to the public interest. At its meeting this week, the committee will feature discussions on both.
US Industry IP Index Released: US Advances, India Shows Leadership, EU, Singapore Near Top 08/02/2019 by David Branigan, Intellectual Property Watch Leave a Comment The leading United States industry association yesterday released its annual International Intellectual Property Index, ranking countries on their progress in protecting US intellectual property rights. The ranks show the US advancing in the area of patent protection, while retaining the top overall score; India strengthening IP and charting a course for other developing countries; and EU countries dominating the higher scoring bracket with Singapore first on patent protection.
Pre-Grant Opposition Filed Against Janssen’s Bedaquiline Fumarate Application In India 08/02/2019 by Intellectual Property Watch 2 Comments Tuberculosis and its variant – Drug Resistant Tuberculosis (DR-TB) – are global public health emergencies. Current treatment regimens are expensive, tedious and prolonged: the overall treatment duration is 20 months or more, requiring daily administration of drugs that are more toxic and less effective than those used to treat drug-susceptible TB. Most of the drugs for treating TB are old and are known to have severe side-effects, writes Sandeep K. Rathod.
IP Still At Heart Of Access To Medicines Discussions At WHO 07/02/2019 by Catherine Saez, Intellectual Property Watch Leave a Comment Intellectual property is often pointed at as hindering access to medicines by resulting in their long-lasting unaffordability, a view which is strongly opposed by IP proponents. The discussions on access to medicines last week during the World Health Organization Executive Board meeting yielded a record number of interventions by member states and nongovernmental organisations, reflecting the importance of the issue.
Trump Highlights IP, Trade, Drug Prices In Speech To Congress 06/02/2019 by William New, Intellectual Property Watch 1 Comment President Donald Trump gave the US Congress a rosy, nationalistic presentation of the condition of the US economy and security last night and amid the range of issues raised, mentioned intellectual property twice in the context of trade, and extensively discussed lowering drug prices.
